According to Cara Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.02 B. In 2020 the company made a revenue of $0.13 B an increase over the years 2019 revenue that were of $0.01 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2022 (TTM) | $0.02 B | |
2020 | $0.13 B | 579.28% |
2019 | $0.01 B | |
2014 | $3.17 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | $94.88 B | 366,472.65% | ๐บ๐ธ USA |
![]() Pfizer PFE | $92.36 B | 356,763.58% | ๐บ๐ธ USA |
![]() Trevena TRVN | $0.37 M | -98.54% | ๐บ๐ธ USA |
![]() Recro Pharma
REPH | $0.07 B | 191.16% | ๐บ๐ธ USA |
![]() Flexion Therapeutics
FLXN | $0.10 B | 287.90% | ๐บ๐ธ USA |
![]() Acorda Therapeutics
ACOR | $0.12 B | 374.22% | ๐บ๐ธ USA |
![]() AcelRx Pharmaceuticals
ACRX | $2.74 M | -89.38% | ๐บ๐ธ USA |